LncRNA LIFR-AS1 Regulated Chemoresistance of Gastric Cancer Cells through Regulating MicroRNA-138-5p-PDK1 Axis
Department of Radiology, Dahua Hospital, Xuhui District, Shanghai 200237, 1Division of Chemistry and Ionizing Radiation Measurement Technology, Shanghai Institute of Measurement and Testing Technology, Pudong, Shanghai 201203, 2Department of Spine Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Hongkou, Shanghai 200437, China
Ke Mei, Department of Radiology, Dahua Hospital, Xuhui District, Shanghai 200237, China, E-mail: firstname.lastname@example.org
Cisplatin represents an important strategy for gastric cancer treatment. However, cisplatin resistance often leads to failure of therapy as well as local reoccurrence. Recently, long non-coding ribonucleic acid was demonstrated to exert important roles in gastric cancer. Expression of long non-coding ribonucleic acid was measured by real time polymerase chain reaction assay in cells from different groups. Cell apoptosis was checked with Hoechst methods and cell counting kit-8 assay was used to determine cell proliferation. Bioinformatics analysis was applied to predict the target of long non-coding ribonucleic acid, which was verified in luciferase assay. We uncovered that long non-coding ribonucleic acid leukemia inhibitory factor receptor antisense RNA1 was significantly correlated to the patient survival of gastric cancer. Knockdown or overexpression of leukemia inhibitory factor receptor antisense RNA1 resulted in delayed or increased cell proliferation in gastric cancer cell lines, respectively. Moreover, in response to cisplatin treatments, cells with leukemia inhibitory factor receptor antisense RNA1 knockdown resulted in more cell apoptosis as well as less colony survival. Leukemia inhibitory factor receptor antisense RNA1 was further confirmed and bound with micro ribonucleic acid-138-5p and then regulates pyruvate dehydrogenase kinase 1 to promote gastric cancer growth. Our findings provided novel mechanism and novel targets for overcoming the cisplatin resistance of gastric cancer.